Outcome of Board Meeting held today i.e., Tuesday, 5th August, 2025.
VCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vaxtex Cotfab's board met on August 5, 2025 and approved unaudited Q1 FY26 results (quarter ended June 30, 2025), reporting revenue from operations of ₹525.33 lakhs and profit after tax of ₹21.60 lakhs, compared to just ₹2.48 lakhs in total income and ₹7.80 lakhs PAT in the same quarter last year — a sharp year-on-year recovery. The board also approved the FY25 director's report, fixed the 20th AGM for September 2, 2025 via video conferencing, and reconstituted the Audit, Nomination & Remuneration, and Stakeholder Relationship Committees. Additionally, Jay Pandya & Associates were appointed as Secretarial Auditors for a five-year term (FY26–FY30), subject to shareholder approval. The statutory auditor (SSRV & Associates) issued an unmodified opinion on the results.
Strong revenue rebound in Q1 FY26 reflects the company's revival after exiting the Corporate Insolvency Resolution Process (CIRP) in January 2025 — a meaningful positive for shareholders. The clean audit opinion and committee restructuring signal improving governance, though the small scale of operations and historically negative reserves warrant continued monitoring.